These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27329502)

  • 21. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.
    Britton RA; Young VB
    Gastroenterology; 2014 May; 146(6):1547-53. PubMed ID: 24503131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
    Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
    mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P2X7 receptor blockade decreases inflammation, apoptosis, and enteric neuron loss during
    Santos AAQA; Costa DVS; Foschetti DA; Duarte ASG; Martins CS; Soares PMG; Castelucci P; Brito GAC
    World J Gastroenterol; 2022 Aug; 28(30):4075-4088. PubMed ID: 36157120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.
    Paparella AS; Aboulache BL; Harijan RK; Potts KS; Tyler PC; Schramm VL
    Nat Commun; 2021 Nov; 12(1):6285. PubMed ID: 34725358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
    Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
    J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human intestinal enteroids as a model of
    Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
    [No Abstract]   [Full Text] [Related]  

  • 27. The microbial-derived bile acid lithocholate and its epimers inhibit
    Kisthardt SC; Thanissery R; Pike CM; Foley MH; Theriot CM
    J Bacteriol; 2023 Sep; 205(9):e0018023. PubMed ID: 37695856
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile.
    Carlucci C; Jones CS; Oliphant K; Yen S; Daigneault M; Carriero C; Robinson A; Petrof EO; Weese JS; Allen-Vercoe E
    Sci Rep; 2019 Jan; 9(1):885. PubMed ID: 30696914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
    Steele J; Mukherjee J; Parry N; Tzipori S
    J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A.
    Huang JH; Shen ZQ; Lien SP; Hsiao KN; Leng CH; Chen CC; Siu LK; Chong PC
    PLoS One; 2015; 10(8):e0135045. PubMed ID: 26271033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human peptide α-defensin-1 interferes with Clostridioides difficile toxins TcdA, TcdB, and CDT.
    Fischer S; Ückert AK; Landenberger M; Papatheodorou P; Hoffmann-Richter C; Mittler AK; Ziener U; Hägele M; Schwan C; Müller M; Kleger A; Benz R; Popoff MR; Aktories K; Barth H
    FASEB J; 2020 May; 34(5):6244-6261. PubMed ID: 32190927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype.
    Buckley AM; Spencer J; Maclellan LM; Candlish D; Irvine JJ; Douce GR
    PLoS One; 2013; 8(5):e64121. PubMed ID: 23704976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
    Lv Z; Peng G; Liu W; Xu H; Su J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
    Cohen OR; Steele JA; Zhang Q; Schmidt DJ; Wang Y; Hamel PE; Beamer G; Xu B; Tzipori S
    PLoS One; 2014; 9(10):e111075. PubMed ID: 25347821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
    Steele J; Parry N; Tzipori S
    Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections.
    Kim J; Pai H; Seo MR; Kang JO
    BMC Infect Dis; 2012 May; 12():109. PubMed ID: 22571633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiota in vitro modulated with polyphenols shows decreased colonization resistance against Clostridioides difficile but can neutralize cytotoxicity.
    Mahnic A; Auchtung JM; Poklar Ulrih N; Britton RA; Rupnik M
    Sci Rep; 2020 May; 10(1):8358. PubMed ID: 32433519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a neutralizing antibody helps identify structural features critical for binding of
    Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
    J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.